- Home
- RAND vs OTLK Comparison
RAND vs OTLK Comparison
Compare RAND & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- OTLK
- Stock Information
- Founded
- RAND 1969
- OTLK 2010
- Country
- RAND United States
- OTLK United States
- Employees
- RAND N/A
- OTLK N/A
- Industry
- RAND Finance: Consumer Services
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAND Finance
- OTLK Health Care
- Exchange
- RAND Nasdaq
- OTLK Nasdaq
- Market Cap
- RAND 57.6M
- OTLK 48.3M
- IPO Year
- RAND N/A
- OTLK 2016
- Fundamental
- Price
- RAND $16.48
- OTLK $1.57
- Analyst Decision
- RAND
- OTLK Strong Buy
- Analyst Count
- RAND 0
- OTLK 5
- Target Price
- RAND N/A
- OTLK $9.60
- AVG Volume (30 Days)
- RAND 5.7K
- OTLK 796.7K
- Earning Date
- RAND 08-05-2025
- OTLK 08-13-2025
- Dividend Yield
- RAND 10.39%
- OTLK N/A
- EPS Growth
- RAND 39.77
- OTLK N/A
- EPS
- RAND 3.12
- OTLK 0.83
- Revenue
- RAND $8,499,970.00
- OTLK N/A
- Revenue This Year
- RAND N/A
- OTLK N/A
- Revenue Next Year
- RAND N/A
- OTLK $379.84
- P/E Ratio
- RAND $5.17
- OTLK $1.91
- Revenue Growth
- RAND 12.52
- OTLK N/A
- 52 Week Low
- RAND $14.01
- OTLK $0.87
- 52 Week High
- RAND $31.89
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- RAND 54.96
- OTLK 40.37
- Support Level
- RAND $15.00
- OTLK $1.65
- Resistance Level
- RAND $15.75
- OTLK $2.04
- Average True Range (ATR)
- RAND 0.34
- OTLK 0.12
- MACD
- RAND 0.20
- OTLK -0.03
- Stochastic Oscillator
- RAND 100.00
- OTLK 2.13
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.